Skip to content

PrOgnostic imPlicaTIons of 2-diMensIonal Patterns for Residual Disease After Stenting CharacteriZEd by Quantitative Flow Ratio Pullback Curve Analysis

PrOgnostic imPlicaTIons of 2-diMensIonal Patterns for Residual Disease After Stenting CharacteriZEd by Quantitative Flow Ratio Pullback Curve Analysis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05125107
Acronym
CHART-OPTIMIZE
Enrollment
1607
Registered
2021-11-18
Start date
2021-11-15
Completion date
2022-03-30
Last updated
2021-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

The purpose of this study is to investigate the prognostic values of 2-dimensional residual disease patterns determined by quantitative flow ratio (QFR) pullbacks after stent implantation.

Detailed description

Prognostic value of post-percutaneous coronary intervention (PCI) percutaneous coronary intervention (PCI) physiology assessment has been confirmed. The rationale for measuring post-PCI physiologic outcome is that it could implicate the residual risk of suboptimal stenting in addition to residual diffuse coronary artery disease after PCI Nevertheless, it should be noted that both post-PCI physiologic indices such as ,fractional flow reserve (FFR) and QFR, are measured at the distal of the interrogated vessel and reflect the cumulative residual disease burdens, defining the residual disease patterns might have additional role in exploring the underlying mechanisms for suboptimal post-PCI physiologic results, thus providing the opportunities for functional optimization with subsequent interventions accordingly to improve immediate functional results, long-term outcomes may be positively affected. Concept of physiologic 2-dimensional disease patterns according to both physiologic distribution (predominant focal versus diffuse disease) and local severity (presence versus absence of major gradient) of coronary atherosclerosis before PCI was proposed and could be derived from virtual QFR pullback curve. Nevertheless, the prognostic value of the 2-dimensional residual disease patterns after PCI has not been studied yet. The CHART-OPTIMIZE study aims to investigate the clinical implications of physiologic 2-dimensional residual disease patterns after stenting.

Interventions

DEVICEQuantitative Flow Ratio derived PPG and dQFR/ds

From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as: PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2 Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)

Sponsors

Chinese Academy of Medical Sciences, Fuwai Hospital
CollaboratorOTHER
Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with at least one vessel with measurable post-PCI QFR * PPG index can be calculated from virtual QFR pullback curve * dQFR/ds can be calculated from virtual QFR pullback curve * The patient is willing to comply with specified follow-up evaluations; * Patients who agree to accept the follow-up visits.

Exclusion criteria

* Culprit vessels for ACS myocardial infarction; * Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure; * Patient has other medical illness (e.g., cancer, known malignancy, congestive heart failure, organ transplant recipient or candidate) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e., less than 1 year); * Patient has a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel/ticlopidine, stainless steel alloy, cobalt chromium, rapamycin, styrene-butylenes-styrene or poly-lactic acid (PLA) polymer, and/or contrast sensitivity that cannot be adequately pre-medicated; * Any significant medical condition which in the Investigator's opinion may interfere with the patient's optimal participation in the study; * Currently participating in another investigational drug or device study or patient in inclusion in another investigational drug or device study during follow-up.

Design outcomes

Primary

MeasureTime frameDescription
Vessel-oriented composite outcomeat 2 years from index procedureVessel-oriented composite outcome (VOCO) including vessel related ischemia-driven target vessel revascularization, vessel-related myocardial infarction (MI), and cardiac death.

Secondary

MeasureTime frameDescription
Cardiac death or vessel-related MIat 2 years from index procedureCardiac death or vessel-related MI
Vessel-related MIat 2 years from index procedureVessel-related MI
Cardiac deathat 2 years from index procedureCardiac death
Ischemia-driven target vessel revascularizationat 2 years from index procedureIschemia-driven target vessel revascularization

Contacts

Primary ContactNeng Dai, MD
niceday1987@hotmail.com+8613701997266

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026